0000899243-20-031922.txt : 20201123 0000899243-20-031922.hdr.sgml : 20201123 20201123164716 ACCESSION NUMBER: 0000899243-20-031922 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201119 FILED AS OF DATE: 20201123 DATE AS OF CHANGE: 20201123 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dallas Jayson Donald Alexander CENTRAL INDEX KEY: 0001650322 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39655 FILM NUMBER: 201338363 MAIL ADDRESS: STREET 1: AIMMUNE THERAPEUTICS, INC. STREET 2: 8000 MARINA BOULEVARD, SUITE 300 CITY: BRISBANE STATE: CA ZIP: 94005 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Galecto, Inc. CENTRAL INDEX KEY: 0001800315 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 371957007 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: GALECTO BIOTECH AB STREET 2: OLE MAALOES VEJ3 CITY: COPENHAGEN STATE: G7 ZIP: DK-2200 BUSINESS PHONE: 45-70-70-52-10 MAIL ADDRESS: STREET 1: GALECTO BIOTECH AB STREET 2: OLE MAALOES VEJ3 CITY: COPENHAGEN STATE: G7 ZIP: DK-2200 FORMER COMPANY: FORMER CONFORMED NAME: Galecto Inc. DATE OF NAME CHANGE: 20200116 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-11-19 0 0001800315 Galecto, Inc. GLTO 0001650322 Dallas Jayson Donald Alexander C/O GALECTO, INC. OLE MAALOES VEJ 3 COPENHAGEN N G7 DK-2200 DENMARK 1 0 0 0 Stock Option (right to buy) 16.60 2020-11-19 4 A 0 18000 0.00 A 2030-11-18 Common Stock 18000 18000 D Stock Option (right to buy) 16.60 2020-11-19 4 A 0 9000 0.00 A 2030-11-18 Common Stock 9000 9000 D The shares subject to such option vest in 36 equal monthly installments over three years from the date of vesting commencement of November 19, 2020, subject to the Reporting Person's continuous service to the Issuer on each such date. Represents a pro-rated annual option grant to a non-employee director upon appointment to the Board of Directors of the Company. The shares subject to such option vest in twelve equal monthly installments, commencing on November 19, 2020, subject to the Reporting Person's continuous service to the Issuer on each such date. /s/ Jonathan Freve, attorney-in-fact 2020-11-23